<--- Back to Details
First PageDocument Content
Pharmacology / Biotechnology / Health care / Recombinant proteins / Pharmaceutical industry / Immunosuppressants / Amgen / Biosimilar / Etanercept / Filgrastim / Hospira / Generic drug
Pharmacology
Biotechnology
Health care
Recombinant proteins
Pharmaceutical industry
Immunosuppressants
Amgen
Biosimilar
Etanercept
Filgrastim
Hospira
Generic drug

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

Add to Reading List

Source URL: www.harvard-jlpp.com

Download Document from Source Website

File Size: 305,00 KB

Share Document on Facebook

Similar Documents

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Press Release  Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

DocID: 1q6vz - View Document

“You Don’t Know What You’re Missing” Evaluating Competitor Clinical Trials with the BizInt Smart Charts Product Family November 2013

“You Don’t Know What You’re Missing” Evaluating Competitor Clinical Trials with the BizInt Smart Charts Product Family November 2013

DocID: 1mfkn - View Document

[ Industry Watch ]  INDIA Intas Plans Filgrastim launch in North America, Europe

[ Industry Watch ] INDIA Intas Plans Filgrastim launch in North America, Europe

DocID: 1kixC - View Document

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid

DocID: 1fBTU - View Document